Sanofi/Regeneron’s Alirocumab Cuts CV Events And Cholesterol
This article was originally published in The Pink Sheet Daily
Executive Summary
A preliminary ad hoc analysis suggests alirocumab has beneficial effects on patient outcomes as well as markedly reducing LDL-cholesterol levels in patients with hypercholesterolemia already treated with maximum doses of statins.